Pharmaceutical composition for treatment of increased intraocular pressure
The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The invention further provides kits comprising such compositions.
1. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a poorly water-soluble prostaglandin analogue selected from the group consisting of latanoprost, bimatoprost, tafluprost, travoprost and unoprostone, and
(b) a liquid vehicle comprising a semifluorinated alkane selected from F4H5, F4H6, F6H6 and F6H8;
wherein the composition is substantially free of water and free of a preservative, and
wherein the composition is formulated as a solution, emulsion or suspension.
2. The composition of claim 1 , wherein the active ingredient is latanoprost.
3. The composition of claim 2 , wherein the concentration of latanoprost is from about 0.001 wt.-% to about 0.01 wt.-%.
4. The composition of claim 1 , wherein the composition is formulated as a solution.
5. The composition of claim 1 , further comprising an organic co-solvent.
6. The composition of claim 5 , comprising ethanol at a concentration of about 1.5 wt.-% or less, or of about 1.0 wt.-% or less.
7. The composition of claim 1 , wherein the semifluorinated alkane is F4H5.
8. The composition of claim 7 , wherein the composition is formulated as a solution.
9. The composition of claim 8 , further comprising an organic co-solvent.
10. The composition of claim 9 , wherein the organic co-solvent is ethanol at a concentration of about 1.5 wt.-% or less.
11. The composition of claim 7 , wherein the active ingredient is latanoprost.
12. The composition of claim 11 , wherein the concentration of latanoprost is from about 0.001 wt.-% to about 0.01 wt.-%.
13. The composition of claim 12 , wherein the composition is formulated as a solution.
14. The composition of claim 13 , further comprising an organic co-solvent.
15. The composition of claim 14 , wherein the organic co-solvent is ethanol at a concentration of about 1.5 wt.-% or less.
16. A pharmaceutical kit comprising the composition of claim 1 and a container holding the composition, wherein the container has a dispensing means.
17. A pharmaceutical kit comprising the composition of claim 11 and a container holding the composition, wherein the container has a dispensing means.